ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Inclusion Criteria:

* Histologically confirmed solid tumors meeting 1 of the following criteria:

  * Progressive disease following standard therapy
  * Disease for which acceptable standard treatment options do not exist
* May have received 0-2 prior chemotherapeutic regimens (single-agent or combination chemotherapies)
* Willing to undergo BRCA mutation analysis

  * Known BRCA mutations allowed
  * All patients, at any dose level, without a known BRCA mutation undergo screening with the BRCAPRO program to assess the likelihood of having a BRCA mutation
  * Patients with a BRCAPRO likelihood of gene mutation of ≥ 20% must undergo BRCA gene testing by the Myriad Genetic Laboratories in order to participate in the study

    * Patients are eligible whether they have a known deleterious BRCA 1 or 2 mutation or a mutation of uncertain significance
* No CNS disease (e.g., brain metastases or glioma)
* No active seizure or history of seizure disorder
* ECOG performance status 0-2 (Karnofsky 60-100%)
* Life expectancy \> 3 months
* ANC ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Bilirubin \< 2.0 mg/dL
* AST and ALT \< 3 times upper limit of normal
* Creatinine normal OR creatinine clearance \> 50 mL/min
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Able to swallow pills
* HIV-positive patients allowed provided that CD4 counts are \< 500 and not on protease inhibitors
* No uncontrolled diarrhea
* No uncontrolled intercurrent illness including, but not limited to, any of the following:

  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Cardiac arrhythmia
  * Psychiatric illness or social situations that would limit compliance with study requirements
* No other concurrent anticancer therapies or agents
* More than 4 weeks since prior major surgery, radiotherapy, or chemotherapy (6 weeks for mitomycin C or nitrosoureas) and recovered
* Prior gemcitabine hydrochloride or PARP inhibition therapy, including ABT-888, allowed

  * No prior combination of gemcitabine hydrochloride and any PARP inhibitor
* Concurrent bisphosphonate IV allowed provided treatment was initiated before study therapy (for patients with bone metastases or hypercalcemia)
* Patients with prostate cancer must continue luteinizing-hormone releasing-hormone agonist therapy and discontinue antiandrogens (≥ 6 weeks since bicalutamide and ≥ 4 weeks since flutamide)
* No other concurrent investigational agents